I-Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
I-Mab presented promising top-line results from its Phase 1 study of givastomig, a bispecific antibody, at ESMO 2024. The study showed promising activity in gastric cancer patients, and the recommended Phase 2 dose was determined to be 8-12 mg/kg.
September 16, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
I-Mab's Phase 1 study of givastomig, a bispecific antibody, shows promising results in gastric cancer patients. The recommended Phase 2 dose is 8-12 mg/kg, and the drug was well tolerated.
The positive results from the Phase 1 study of givastomig, including its tolerability and efficacy in gastric cancer patients, are likely to boost investor confidence in I-Mab. The determination of a recommended Phase 2 dose further supports the drug's development progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100